Wattakaka volubilis

Wattakaka volubilis contains polyoxypregnane glycosides (volubilosides A, B, and C), flavonoids (kaempferol, quercetin, rutin), terpenoids (ursolic acid, oleanolic acid), and cardiac glycoside-related constituents that contribute to its expectorant, anti-asthmatic, antioxidant, and gastroprotective activities through multi-target pharmacological mechanisms. In preclinical models, leaf extracts demonstrated 83.44% DPPH radical inhibition at 200 mg/mL, α-glucosidase inhibition with an IC50 of 38.58 μg/mL, and significant gastric ulcer protection of up to 70.58% at 500 mg/kg oral dosing in rodents.

Origin & History

Wattakaka volubilis is a woody climbing vine native to tropical and subtropical regions of South and Southeast Asia, including India, Sri Lanka, Myanmar, Thailand, and southern China, where it grows in forest margins, scrublands, and along riverbanks at low to moderate elevations. The plant thrives in warm, humid conditions with well-drained soils and is commonly found twining over hedges and trees in both wild and semi-cultivated settings. In India, it is particularly prevalent across the Western Ghats, the Deccan Plateau, and the eastern coastal regions, where it has been harvested from wild populations for use in Ayurvedic and tribal folk medicine.

Historical & Cultural Context

Wattakaka volubilis, known by regional names such as 'Dumnasparee' in Tamil and 'Kokkilam' in certain South Indian traditions, has been documented as a component of Ayurvedic medicine and tribal folk healing practices across the Indian subcontinent for generations. Ethnobotanical surveys of indigenous communities in Tamil Nadu, Andhra Pradesh, and Kerala have recorded its use as a remedy for asthma, cough, bronchitis, fever, skin diseases, and rheumatic complaints, with different plant parts—bark, leaves, roots, and flowers—each assigned specific therapeutic roles. The plant belongs to the family Apocynaceae (formerly Asclepiadaceae) and shares phytochemical kinship with other medically significant members of this family, including species of Calotropis and Hoya, lending historical credibility to its cardiac and respiratory applications. References to plants within this botanical family appear in classical Ayurvedic texts such as the Charaka Samhita and regional tribal pharmacopoeias, though Wattakaka volubilis itself is more prominently featured in contemporary ethnobotanical documentation than in ancient canonical texts.

Health Benefits

- **Expectorant and Anti-Asthmatic Activity**: Cardiac glycoside-related constituents and pregnane glycosides are believed to reduce airway inflammation and promote mucus clearance, supporting the plant's traditional use as a remedy for cough, asthma, and bronchitis in Indian folk medicine.
- **Antioxidant Protection**: Leaf extracts exhibited robust free-radical scavenging, including 83.44% DPPH inhibition, 80.04% superoxide inhibition, and 86.96% hydroxyl radical inhibition at 200 mg/mL, attributable to the combined action of quercetin, kaempferol, rutin, and ursolic acid.
- **Gastroprotective Effects**: In rat models of ethanol-induced gastric ulcers, oral administration of W. volubilis extract at 500 mg/kg significantly reduced ulcer index scores and conferred up to 70.58% gastric protection, likely through mucosal strengthening and antioxidant mechanisms.
- **Antimicrobial Activity**: Extracts at 750 μg/mL produced inhibition zones of 27.8 mm against Escherichia coli and 22.6 mm against Bacillus subtilis, with minimum inhibitory concentrations ranging from 500–1000 μg/mL, attributed to the synergistic activity of alkaloids, tannins, and terpenoids.
- **Anti-Diabetic Potential**: Leaf extracts inhibited α-glucosidase with an IC50 of 38.58 μg/mL and α-amylase with an IC50 of 60.51 μg/mL, suggesting the potential to attenuate postprandial glucose spikes through enzymatic inhibition, likely mediated by flavonoids and ursolic acid.
- **Cytotoxic and Anticancer Activity**: The extract demonstrated moderate cytotoxicity against HeLa cervical cancer cells (CTC50 of 210 μg/mL) and against MCF-7 breast cancer cells (CTC50 below 1000 μg/mL), indicating preliminary antiproliferative potential warranting further mechanistic investigation.
- **Anti-Inflammatory and Immunomodulatory Properties**: Triterpenoids including oleanolic acid, ursolic acid, and taraxerol present in the plant are established inhibitors of pro-inflammatory mediators such as NF-κB and COX enzymes in other botanical contexts, supporting the traditional use of W. volubilis in inflammatory and febrile conditions.

How It Works

The pregnane glycosides—volubilosides A, B, and C—and cardiac glycoside-like constituents may exert their expectorant and anti-asthmatic effects by modulating ion transport across airway epithelial cells, analogous to other Asclepiadaceae-family cardiac glycosides that inhibit Na⁺/K⁺-ATPase pumps, thereby altering intracellular calcium signaling and bronchial smooth muscle tone. Flavonoids such as quercetin and kaempferol scavenge reactive oxygen species directly and inhibit xanthine oxidase and lipoxygenase enzymes, reducing oxidative and inflammatory cascades implicated in respiratory and metabolic diseases. Ursolic acid and oleanolic acid, pentacyclic triterpenoids present in the plant, are known to suppress NF-κB transcriptional activity and downregulate cyclooxygenase-2 (COX-2) expression, contributing to anti-inflammatory and gastroprotective outcomes. The α-glucosidase and α-amylase inhibition observed in vitro is likely attributable to competitive or mixed-type inhibition by flavonoid glycosides such as rutin and kaempferol 3-galactoside, which structurally mimic carbohydrate substrates and bind to the enzyme active sites.

Scientific Research

The current body of evidence for Wattakaka volubilis consists almost entirely of in vitro assays and animal model studies, with no published human randomized controlled trials identified in the peer-reviewed literature to date. Preclinical studies have assessed antioxidant capacity using DPPH, FRAP, superoxide, and nitric oxide scavenging assays; antibacterial efficacy against gram-positive and gram-negative pathogens; cytotoxicity against human cancer cell lines (HeLa, MCF-7); and gastroprotection in ethanol-induced ulcer rat models using doses of 500 mg/kg. Toxicity profiling via brine shrimp lethality assay reported an LC50 of 644.99 μg/mL for petroleum ether extracts, indicating moderate biological activity. The evidence base is preliminary and the translation of these findings to human therapeutic recommendations is not yet supported; authors of the primary studies explicitly note that well-designed in vivo and clinical trials are imperative before medicinal use can be substantiated.

Clinical Summary

No human clinical trials have been conducted on Wattakaka volubilis as of the available literature. All pharmacological outcome data derives from in vitro cell-based assays and rodent pharmacology experiments, which represent early-stage preclinical evidence. Outcomes measured include ulcer protection rates (up to 70.58% at 500 mg/kg), enzyme inhibition IC50 values for anti-diabetic endpoints, inhibition zone diameters for antimicrobial activity, and CTC50 values for anticancer cytotoxicity—none of which have been validated in human subjects. Confidence in translating these results to clinical recommendations is low, and the ingredient should be regarded as investigational pending rigorous Phase I/II clinical evaluation.

Nutritional Profile

Wattakaka volubilis is not consumed as a food ingredient and lacks a conventional macronutrient or dietary nutritional profile. Phytochemically, its leaves and bark are rich in bioactive secondary metabolites: flavonoids including quercetin, kaempferol, kaempferol 3-galactoside, rutin, apigenin, and luteolin; novel polyoxypregnane glycosides (volubilosides A, B, C); pentacyclic triterpenoids including ursolic acid (~trace to moderate concentrations), oleanolic acid, and taraxerol; the phytosterol β-sitosterol; the triterpene alcohol squalene; and long-chain hydrocarbons (octacosane, hexacosane, heptacosane). Tannins, alkaloids, and free amino acids are also present across bark, leaf, flower, and fruit fractions. Bioavailability of key constituents such as quercetin and ursolic acid is expected to be moderate in their glycoside forms and improved by lipid co-administration based on pharmacokinetic principles established for structurally analogous compounds in other plant species.

Preparation & Dosage

- **Traditional Decoction (Bark/Leaf)**: Approximately 5–10 g of dried plant material boiled in 200–300 mL water, strained, and consumed once or twice daily as a traditional Ayurvedic or folk remedy for respiratory complaints; exact standardization is not established.
- **Methanol or Hydro-Alcoholic Extract**: Used in laboratory studies at concentrations of 100–750 μg/mL for in vitro testing; no standardized commercial extract or human-equivalent dose has been defined.
- **Petroleum Ether Extract**: Employed in toxicity and phytochemical fractionation studies; the LC50 of 644.99 μg/mL in brine shrimp assay suggests caution at high concentrations.
- **Acetone Extract**: Used in antimicrobial disk-diffusion assays at 750 μg/mL; not formulated for human supplementation.
- **Animal Study Reference Dose**: 500 mg/kg oral dose used in gastroprotection rodent models; direct extrapolation to human dosing is not scientifically validated and should not be attempted without clinical guidance.
- **Standardization**: No commercial standardization percentage (e.g., percentage of volubilosides or quercetin) has been established or validated for this ingredient.

Synergy & Pairings

In traditional Ayurvedic and folk formulations, W. volubilis is sometimes combined with Adhatoda vasica (Malabar nut) and Glycyrrhiza glabra (licorice root) for respiratory complaints, a combination that theoretically enhances bronchodilatory and expectorant activity through complementary alkaloid (vasicine in Adhatoda) and saponin (glycyrrhizin) mechanisms alongside the pregnane glycosides of Wattakaka. The flavonoids quercetin and kaempferol present in the plant may exhibit enhanced bioavailability and antioxidant synergy when co-administered with piperine from black pepper (Piper nigrum), which inhibits UDP-glucuronosyltransferase and P-glycoprotein efflux—a mechanism well-established for quercetin absorption enhancement. Co-formulation with lipid-based carriers or medium-chain triglycerides may further improve the absorption of its fat-soluble terpenoid constituents, including ursolic acid, oleanolic acid, and β-sitosterol.

Safety & Interactions

Human safety data for Wattakaka volubilis is not available, and the ingredient has not been assessed in clinical toxicology or pharmacovigilance studies in human populations. In preclinical brine shrimp lethality assays, the petroleum ether extract yielded an LC50 of 644.99 μg/mL, indicating moderate biological toxicity at elevated concentrations; animal studies at various extract doses also showed changes in serum urea, creatinine, sodium, potassium, α-amylase, and glucose levels, suggesting potential renal and metabolic effects at high doses. The presence of cardiac glycoside-related pregnane glycosides raises a theoretical concern for cardiotoxicity, particularly in individuals taking digoxin, other cardiac glycosides, antiarrhythmic agents, or diuretics, as additive Na⁺/K⁺-ATPase inhibition could alter cardiac electrophysiology. Wattakaka volubilis should be avoided during pregnancy and lactation in the absence of safety data, and its use in individuals with renal impairment, cardiac conditions, or those on narrow therapeutic index medications should be considered contraindicated until human safety studies are completed.